vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and TAO Synergies Inc. (TAOX). Click either name above to swap in a different company.
TAO Synergies Inc. is the larger business by last-quarter revenue ($203.4K vs $115.4K, roughly 1.8× CytoMed Therapeutics Ltd).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
Tao Group Hospitality is an American restaurant and nightlife conglomerate founded in 2009 and headquartered in New York City. The group, whose roots can be traced to as early as 2000, presently owns and operates restaurants, nightclubs, dayclubs, private event venues, and food delivery services under 44 brands.
GDTC vs TAOX — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $203.4K |
| Net Profit | — | $-3.9M |
| Gross Margin | — | — |
| Operating Margin | — | -884.8% |
| Net Margin | — | -1929.1% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 31.7% |
| EPS (diluted) | — | $-1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $16.1M |
| Total Assets | — | $18.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $16.1M | ||
| Q2 25 | — | — |
| Q3 25 | — | $18.4M | ||
| Q2 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | $-1.2M |
| Free Cash FlowOCF − Capex | $-855.4K | — |
| FCF MarginFCF / Revenue | -741.5% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-855.3K | — |
| Q3 25 | — | — | ||
| Q2 25 | $-855.4K | — |
| Q3 25 | — | — | ||
| Q2 25 | -741.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
